Shikonin demonstrates synergistic effects when combined with the PI3K-Akt-mTOR inhibitor BEZ235, significantly reducing the viability of chemotherapy-resistant lung cancer cells (Huang et al., 2024). The gene discussed is MTOR; the disease is lung carcinoma.